Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

pect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the effect of the completion of the Phase 2 clinical trial for Amigal(TM) for the treatment of Fabry disease, the plans for the Phase 3 clinical trial for Amigal(TM), the Phase 2 clinical trials for Plicera(TM) for the treatment of Gaucher disease and the effect of the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease. In addition, the amount and impact of stock- based compensation charges, royalty fees, and pre-tax charges for preferred stock accretion and warrant liability and Amicus' definition of "non-GAAP net income" and/or "non-GAAP net income per share" do not constitute guarantees of future performance and are subject to a variety of risks and uncertainties that could cause its actual results to differ materially from those anticipated. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forward- looking statements are qualified in their entirety by this cautionary statement and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD -G

Table 1

Amicus Therapeutics, Inc.


'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- According to a new market research ... Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem Cells, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 2,150.48 Million in 2015, ... 2020. Browse 74 Tables and 95 ...
(Date:8/28/2015)... ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early ... excellent customer service. Images such as the Fonz in a lab coat and Large ... to the humdrum spectroscopy field. , FireflySci is proud to be the only ...
(Date:8/27/2015)... The National Necrotizing Fasciitis Foundation ... by doctors at Vanderbilt University Hospital in ... and Dr. John Crew , director of the ... Center in Daly City, CA. ... pioneered by Dr. Crew, that had previously saved the ...
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... Joseph Fox 1 , Joanne B. Connolly ... 1 Shimadzu Scientifi c Inc., Columbia, US; ... , Introduction , ... no separation) acquisitions for the analysis of complex peptide mixtures. These include (i) ...
... Introduction , ... serial,dilution of reagents or compounds. IC 50 assays,are commonly used to ... the serial dilution,of proteins, compounds, or other detection,agents. These processes can be ... , , ...
... Introduction , ... ODS-100V and TSKgel ODS-100Z, excellent chromatographic performance and , ... sample types. TSKgel ODS-100Z , and TSKgel ODS-100V ... with 100 angstrom pores; each material is derivatized with difunctional , ...
Cached Biology Technology:LC-MALDI and MALDI-MS/MS for the Analysis of Complex Peptide Mixtures 2LC-MALDI and MALDI-MS/MS for the Analysis of Complex Peptide Mixtures 3LC-MALDI and MALDI-MS/MS for the Analysis of Complex Peptide Mixtures 4Serial Dilution with the Bravo Liquid Handling Platform 2Serial Dilution with the Bravo Liquid Handling Platform 3Serial Dilution with the Bravo Liquid Handling Platform 4Serial Dilution with the Bravo Liquid Handling Platform 5Serial Dilution with the Bravo Liquid Handling Platform 6Serial Dilution with the Bravo Liquid Handling Platform 7Serial Dilution with the Bravo Liquid Handling Platform 8Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins 2Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins 3
(Date:8/12/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that four of its fingerprint ID products, ... been named FIDO Certified™ by the Fast IDentity ... Synaptics, Natural ID™ fingerprint solutions are fully compliant ... standard and are interoperable among other products and ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... , August 5, 2015 Transparency ... "Facial Recognition Market - Global Industry Analysis, Size, Share, ... market for facial recognition is forecast to reach US$ ... increased demand for surveillance systems by civil and government ... of crimes and terrorist activities across the globe that ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... upset by a social snubbing? Your genetics, not your friends, ... opium-like painkillers, called opioids, relieve not only physical pain, but ... reviewed by Faculty of 1000 Biology member Markus Heilig shows ... receptor can determine the intensity of people,s responses to social ...
... low in Antarctic snowmelt that occurred during the 2008-09 austral ... two main climate drivers, ENSO (El Nio - Southern Oscillation) ... Tedesco, Assistant Professor of Earth & Atmospheric Sciences at The ... who is also on the doctoral faculty at the CUNY ...
... within minutes after waking up have much higher levels of ... than those who wait to smoke, regardless of the number ... appear to reflect the risk of lung cancer, our results ... especially at risk for lung cancer," said researcher Joshua E. ...
Cached Biology News:CCNY professor foresees rising Antarctic snowmelt 2Increased nicotine levels detected in those who light-up earlier 2
... CYCLES. An assay kit designed to detect ... PARP is an enzyme implicated in DNA ... is cleaved by caspase-3. Cleavage of PARP ... kDa is a hallmark of apoptosis. Each ...
... The Digital Clamp One can operate as ... as a Conductance (Dynamic) Clamp in electrophysiology research ... good as conventional analog equipment. • ... by very recent advances in the capabilities of ...
... but comes with a shutter (controlled via a ... The DH-2000 Deuterium Tungsten Halogen ... and tungsten halogen light sources in a single ... powerful, stable output from 215-200 nm. In addition, ...
... expressed in g per ml and is determined ... 6.8, of a 1 mg per ml solution. ... to agglutinate a 2% suspension of human blood ... 25 C. Preparation Note: Affinity purified ...
Biology Products: